Penumbra, Inc.
PEN
Classificação em ações
#1679
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Preço da ação
$323.99
Valor de mercado
$12.76B
Variação (1 dia)
0.38%
Variação (1 ano)
30.84%
País
US
Negociar Penumbra, Inc. (PEN)
Categoria
Healthcare
Rácio P/E de Penumbra, Inc. (PEN)
Rácio P/E em October 2026 TTM: 78.27
De acordo com os últimos relatórios financeiros e o preço das ações da Penumbra, Inc., o rácio P/E atual (TTM) é 78.27. No final de 2023, a empresa tinha um P/E de 106.20.
Histórico do rácio P/E da Penumbra, Inc. de 2012 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 78.27 | -88.05% |
| 2024 | 654.78 | 516.55% |
| 2023 | 106.20 | -102.53% |
| 2022 | -4.20K | -310.34% |
| 2021 | 2.00K | -601.49% |
| 2020 | -398.62 | -438.38% |
| 2019 | 117.80 | -82.37% |
| 2018 | 668.05 | 0.25% |
| 2017 | 666.36 | 407.88% |
| 2016 | 131.20 | -51.92% |
| 2015 | 272.88 | -39.48% |
| 2014 | 450.91 | 82.58% |
| 2013 | 246.96 | -52.23% |
| 2012 | 517.00 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 33.11 | -57.70% |
US
|
|
| 21.39 | -72.67% |
IE
|
|
| 28.94 | -63.02% |
US
|
|
| 17.34 | -77.85% |
US
|
|
| - | - |
DE
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.